Dr. Alexander Drilon, MD
Claim this profileMemorial Sloan Kettering Cancer Center
Area of expertise
Non-Small Cell Lung Cancer
Alexander Drilon, MD has run 6 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Solid Tumors
Alexander Drilon, MD has run 6 trials for Solid Tumors. Some of their research focus areas include:
Affiliated Hospitals
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center PHASE 1 (recruiting) & PHASE 2 (Recruiting)
Clinical Trials Alexander Drilon, MD is currently running
NVL-655
for NSCLC
This trial is testing a new drug called NVL-655 to see if it is safe and effective for patients with advanced ALK-positive lung cancer and other solid tumors. The drug works by blocking a protein that helps cancer cells grow. The study focuses on patients who have specific genetic changes and may not respond well to standard treatments. Newer treatments have been shown to improve outcomes in ALK-translocated lung cancer compared to older treatments.
Recruiting
1 award
Phase 1 & 2
7 criteria
Repotrectinib
for Solid Tumors
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
Recruiting
1 award
Phase 1 & 2
7 criteria
More about Alexander Drilon, MD
Clinical Trial Related
4 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Alexander Drilon, MD has experience with
- Cabozantinib
- Repotrectinib (TPX-0005)
- ELU001
- TPX-0046
- NVL-655
- NVL-520
Breakdown of trials Alexander Drilon, MD has run
Non-Small Cell Lung Cancer
Solid Tumors
Lung Cancer
Metastatic Tumor
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alexander Drilon, MD specialize in?
Alexander Drilon, MD focuses on Non-Small Cell Lung Cancer and Solid Tumors. In particular, much of their work with Non-Small Cell Lung Cancer has involved RET positive patients, or patients who are Stage IV.
Is Alexander Drilon, MD currently recruiting for clinical trials?
Yes, Alexander Drilon, MD is currently recruiting for 4 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Alexander Drilon, MD has studied deeply?
Yes, Alexander Drilon, MD has studied treatments such as Cabozantinib, Repotrectinib (TPX-0005), ELU001.
What is the best way to schedule an appointment with Alexander Drilon, MD?
Apply for one of the trials that Alexander Drilon, MD is conducting.
What is the office address of Alexander Drilon, MD?
The office of Alexander Drilon, MD is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.